MX2015016283A - METODOS PARA TRATAR AFECCIONES INFLAMATORIAS UTILIZANDO S-[4-(3-FLUORO-3-METILBUTIRILOXI) BUT-2-INIL] 6A, 9A-DIFLUORO-17A- (FURAN-2-IL) CARBONILOXI-11ß-HIDROXI-16A - METIL-3-OXOANDROSTA-1,4-DIEN-17ß - CARBOTIOATO. - Google Patents

METODOS PARA TRATAR AFECCIONES INFLAMATORIAS UTILIZANDO S-[4-(3-FLUORO-3-METILBUTIRILOXI) BUT-2-INIL] 6A, 9A-DIFLUORO-17A- (FURAN-2-IL) CARBONILOXI-11ß-HIDROXI-16A - METIL-3-OXOANDROSTA-1,4-DIEN-17ß - CARBOTIOATO.

Info

Publication number
MX2015016283A
MX2015016283A MX2015016283A MX2015016283A MX2015016283A MX 2015016283 A MX2015016283 A MX 2015016283A MX 2015016283 A MX2015016283 A MX 2015016283A MX 2015016283 A MX2015016283 A MX 2015016283A MX 2015016283 A MX2015016283 A MX 2015016283A
Authority
MX
Mexico
Prior art keywords
methylbutyryloxy
carbothioate
ynyl
carbonyloxy
difluoro
Prior art date
Application number
MX2015016283A
Other languages
English (en)
Spanish (es)
Inventor
Rajamannar Thennati
Chitturi Trinadha Rao
Jiten Ranchhodbhai Patel
Gopalkumar Chimanlal Patel
Gaurav Sanjivkumar Sheth
Sanjay Nandlal Mandhane
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of MX2015016283A publication Critical patent/MX2015016283A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J3/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
MX2015016283A 2013-05-28 2014-05-28 METODOS PARA TRATAR AFECCIONES INFLAMATORIAS UTILIZANDO S-[4-(3-FLUORO-3-METILBUTIRILOXI) BUT-2-INIL] 6A, 9A-DIFLUORO-17A- (FURAN-2-IL) CARBONILOXI-11ß-HIDROXI-16A - METIL-3-OXOANDROSTA-1,4-DIEN-17ß - CARBOTIOATO. MX2015016283A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1881MU2013 2013-05-28
PCT/IN2014/000359 WO2014192027A1 (en) 2013-05-28 2014-05-28 Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate.

Publications (1)

Publication Number Publication Date
MX2015016283A true MX2015016283A (es) 2016-03-11

Family

ID=51300796

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016283A MX2015016283A (es) 2013-05-28 2014-05-28 METODOS PARA TRATAR AFECCIONES INFLAMATORIAS UTILIZANDO S-[4-(3-FLUORO-3-METILBUTIRILOXI) BUT-2-INIL] 6A, 9A-DIFLUORO-17A- (FURAN-2-IL) CARBONILOXI-11ß-HIDROXI-16A - METIL-3-OXOANDROSTA-1,4-DIEN-17ß - CARBOTIOATO.

Country Status (18)

Country Link
US (1) US9458187B2 (OSRAM)
EP (1) EP3004133B1 (OSRAM)
JP (1) JP6366696B2 (OSRAM)
KR (1) KR20160030085A (OSRAM)
CN (1) CN105431445A (OSRAM)
AU (1) AU2014272640B2 (OSRAM)
BR (1) BR112015029530A8 (OSRAM)
CA (1) CA2912400A1 (OSRAM)
EA (1) EA027831B9 (OSRAM)
ES (1) ES2664019T3 (OSRAM)
IL (1) IL242658A0 (OSRAM)
MX (1) MX2015016283A (OSRAM)
MY (1) MY179214A (OSRAM)
PH (1) PH12015502652A1 (OSRAM)
SG (1) SG11201509680TA (OSRAM)
UA (1) UA117248C2 (OSRAM)
WO (1) WO2014192027A1 (OSRAM)
ZA (1) ZA201508640B (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014272640B2 (en) 2013-05-28 2018-04-05 Sun Pharma Advanced Research Company Limited Methods for treatment of inflammatory conditions using S-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate.
CN107428796A (zh) * 2015-01-31 2017-12-01 太阳医药高级研究有限公司 S‑(4‑(3‑氟‑3‑甲基丁酰氧基)丁‑2‑炔基)6α,9α‑二氟‑17α‑(呋喃‑2‑基)羰氧基‑11β‑羟基‑16α‑甲基‑3‑氧代雄甾‑1,4‑二烯‑17β‑硫代羧酸酯的结晶形式
CN106279341A (zh) * 2015-05-11 2017-01-04 正大天晴药业集团股份有限公司 一种糠酸氟替卡松的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA81976B (en) 1980-02-15 1982-07-28 Glaxo Group Ltd Androstane carbothioates
AU2003263575A1 (en) 2002-06-20 2004-01-06 Sun Pharmaceutical Industries Limited Convenient synthesis of s-fluoromethyl 6alpha, 9alpha-difluoro-11beta-hydroxy-16alpha- methyl-17alpha-propionyloxy-3-oxoandrosta-1, 4-diene-17beta-carbothioate
GB0225287D0 (en) 2002-10-30 2002-12-11 Glaxo Group Ltd Novel compounds
AR059216A1 (es) * 2006-01-27 2008-03-19 Sun Pharmaceutical Ind Ltd 11b-hidroxiandrosta-4-eno-3-onas
AU2014272640B2 (en) 2013-05-28 2018-04-05 Sun Pharma Advanced Research Company Limited Methods for treatment of inflammatory conditions using S-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate.

Also Published As

Publication number Publication date
EP3004133B1 (en) 2018-03-07
EA027831B9 (ru) 2017-12-29
BR112015029530A8 (pt) 2019-12-17
EP3004133A1 (en) 2016-04-13
IL242658A0 (en) 2016-02-01
AU2014272640A1 (en) 2015-11-26
ES2664019T3 (es) 2018-04-18
JP2016520122A (ja) 2016-07-11
US9458187B2 (en) 2016-10-04
AU2014272640B2 (en) 2018-04-05
EA201592283A1 (ru) 2016-04-29
US20160102117A1 (en) 2016-04-14
SG11201509680TA (en) 2015-12-30
WO2014192027A1 (en) 2014-12-04
KR20160030085A (ko) 2016-03-16
CA2912400A1 (en) 2014-12-04
EA027831B1 (ru) 2017-09-29
BR112015029530A2 (pt) 2017-07-25
JP6366696B2 (ja) 2018-08-01
PH12015502652A1 (en) 2016-03-07
UA117248C2 (uk) 2018-07-10
ZA201508640B (en) 2017-09-27
MY179214A (en) 2020-11-02
CN105431445A (zh) 2016-03-23

Similar Documents

Publication Publication Date Title
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
JO3466B1 (ar) مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
SG10201804471PA (en) Bromodomain inhibitors
MX2016002794A (es) Compuestos antiproliferativos.
GT201500235A (es) Estra -1,3,5 (10) , 16- tetraeno -3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1c3)
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
BR112015029462A2 (pt) Inibidores de quinase
NZ711192A (en) Process for making benzoxazepin compounds
EA201500931A1 (ru) Производные пиридин-4-ила
AU2016204294A1 (en) Solid State Forms Of A Quinazoline Derivative And Its Use As A BRAF Inhibitor
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
EA201690763A1 (ru) Лечение рака поджелудочной железы
EA201690227A1 (ru) Азаиндольные соединения, их получение и способы их применения
EA201270728A1 (ru) Пуриновые соединения
UA113988C2 (xx) Спосіб стабілізації бета-напівгідрату штукатурного гіпсу
EA201690594A1 (ru) Состав для лечения вич-инфекции на основе атазанавира и кобицистата
PH12015502652A1 (en) Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate.
MX2020000873A (es) Derivados de ácidos biliares marcados isotópicamente.
MX2015016603A (es) Composiciones de corticosteroides.
EA201591449A1 (ru) Способы получения противораковых композиций
PH12017501360A1 (en) Crystalline form of s-(4-3-fluoro-3-methylbutyryloxy)but-2-ynyl)6a,9a-difluoro-17a,-(fluran-2-yl) carbonyloxy-11b-hydroxy-16a-methy1-3-oxoandrosta-1,4-diene-17b-carbothioate
EA201270727A1 (ru) Пуриновые соединения
MX2018011117A (es) Forma cristalina.
IN2013MU02279A (OSRAM)
IN2015KO00268A (OSRAM)

Legal Events

Date Code Title Description
HH Correction or change in general